Toxic neuropathies.
Journal
Current opinion in neurology
ISSN: 1473-6551
Titre abrégé: Curr Opin Neurol
Pays: England
ID NLM: 9319162
Informations de publication
Date de publication:
01 10 2023
01 10 2023
Historique:
medline:
11
9
2023
pubmed:
28
8
2023
entrez:
28
8
2023
Statut:
ppublish
Résumé
Immunotherapy has had a significant impact on the treatment of an increasing number of cancers as well as in inflammatory, rheumatological and gastroenterological conditions.Recreational nitrous oxide use is now a global epidemic. Linezolid is now recommended for the treatment of drug-resistant tuberculosis (TB); neuropathy is a significant cause of morbidity.Global warming will result in increasing toxin exposure, such as ciguatera, in previously unaffected areas. With increasing experience, the pathophysiology underlying the neuropathic complications of these drugs has become clear with guidelines now available, for the complications of immune check-point inhibitors and nitrous oxide toxicity. The optimum dose and duration of treatment for resistant TB with regimens, including linezolid, has been ascertained. Although neuropathic complications with immunotherapy are relatively rare, it is essential that they are recognized and treated early. Nitrous oxide toxicity should be in the differential diagnosis for all patients, particularly those of younger age, presenting with a neuropathy or myleo-neuropathy. Ciguatera toxicity is under recognized and its geographical spread will increase due to global warming. Further research is necessary on the mechanisms and treatment of both acute and chronic effects, which at present, are only symptomatic.
Identifiants
pubmed: 37639472
doi: 10.1097/WCO.0000000000001193
pii: 00019052-990000000-00096
doi:
Substances chimiques
Linezolid
ISQ9I6J12J
Nitrous Oxide
K50XQU1029
Types de publication
Review
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
402-409Subventions
Organisme : Department of Health
Pays : United Kingdom
Informations de copyright
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Références
Hill AB. The environment and disease: association or causation? Proc R Soc Med 1965; 58:295–300.
Shimonovich M, Pearce A, Thomson H, et al. Assessing causality in epidemiology: revisiting Bradford Hill to incorporate developments in causal thinking. Eur J Epidemiol 2021; 36:873–887.
Bruna J, Argyriou AA, Anastopoulou GG, et al. Incidence and characteristics of neurotoxicity in immune checkpoint inhibitors with focus on neuromuscular events: experience beyond the clinical trials. J Peripher Nerv Syst 2020; 25:171–177.
Dubey D, David WS, Amato AA, et al. Varied phenotypes and management of immune checkpoint inhibitor-associated neuropathies. Neurology 2019; 93:e1093–e1103.
Khan E, Shrestha AK, Elkhooly M, et al. CNS and PNS manifestation in immune checkpoint inhibitors: a systematic review. J Neurol Sci 2022; 432:120089.
Chompoopong P, Zekeridou A, Shelly S, et al. Comparison of immune checkpoint inhibitor-related neuropathies among patients with neuroendocrine and nonneuroendocrine tumours. J Neurol Neurosurg Psychiatry 2022; 93:112–114.
Müller-Jensen L, Knauss S, Ginesta Roque L, et al. Autoantibody profiles in patients with immune checkpoint inhibitor-induced neurological immune related adverse events. Front Immunol 2023; 14:1108116.
Brahmer JR, Abu-Sbeih H, Ascierto PA, et al. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. J Immunother cancer 2021; 9:e002435.
Snavely A, Pérez-Torres EJ, Weber JS, et al. Immune checkpoint inhibition in patients with inactive preexisting neuromuscular autoimmune diseases. J Neurol Sci 2022; 438:120275.
Taha T, Tzuk-Shina T, Forschner I, Bar-Sela G. Acute motor and sensory axonal neuropathy related to treatment with MEK inhibitors in a patient with advanced melanoma. Melanoma Res 2017; 27:632–634.
Maurice C, Marcus B, Mason W. Guillain-Barre syndrome after treatment with dabrafenib for metastatic recurrent melaloma (P4.232). Neurology 2015; 84 (P4):232.
Devic P, Amini-Adle M, Camdessanché JP, Dalle S. Demyelinating polyradiculoneuropathy under combined BRAF/MEK inhibitors. Eur J Cancer 2017; 78:103–104.
Boasberg PD, Redfern CH, Daniels GA, et al. Pilot study of PD-0325901 in previously treated patients with advanced melanoma, breast cancer, and colon cancer. Cancer Chemother Pharmacol 2011; 68:547–552.
Picca A, Birzu C, Berzero G, et al. Peripheral neuropathies after BRAF and/or MEK inhibitor treatment: a pharmacovigilance study. Br J Clin Pharmacol 2022; 88:4941–4949.
Prince HM, Kim YH, Horwitz SM, et al. Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. Lancet 2017; 390:555–566.
Mariotto S, Tecchio C, Sorio M, et al. Clinical and neurophysiological serial assessments of brentuximab vedotin-associated peripheral neuropathy. Leuk Lymphoma 2019; 60:2806–2809.
Fargeot G, Dupel-Pottier C, Stephant M, et al. Brentuximab vedotin treatment associated with acute and chronic inflammatory demyelinating polyradiculoneuropathies. J Neurol Neurosurg Psychiatry 2020; 91:786–788.
Charles PJ, Smeenk RJ, De Jong J, et al. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials. Arthritis Rheum 2000; 43:2383–2390.
Ramos-Casals M, Alvarez RP, Diaz-Lagares C, et al. Autoimmune diseases induced by biological agents. A double-edged sword? Autoimmun Rev 2010; 9:188–193.
Stübgen J-P. Tumor necrosis factor-α antagonists and neuropathy. Muscle Nerve 2008; 37:281–292.
Lassen HC, Henriksen E, Neukirch F, Kristensen HS. Treatment of tetanus; severe bone-marrow depression after prolonged nitrous-oxide anaesthesia. Lancet (London, England) 1956; 270:527–530.
Amess JA, Burman JF, Rees GM, Nancekievill DG. Megaloblastic haemopoiesis in patients receiving nitrous oxide. Lancet (London, England) 1978; 2:339–342.
Advisory council on the misuse of drugs: Nitrous oxide harms and assessment. 2023. https://www.gov.uk/government/publications/nitrous-oxide-updated-harms-assessment/nitrous-oxide-updated.pdf
Winstock A. GDS2020 key findings report. Glob Drug Surv. [date unknown]. https://www.globaldrugsurvey.com/wp-content/uploads/2021/01/GDS2020-Executive-Summary.pdf
Redmond J, Cruse B, Kiers L. Nitrous oxide-induced neurological disorders: an increasing public health concern. Intern Med J 2022; 52:740–744.
McCormick JP, Sharpe S, Crowley K, et al. Nitrous oxide-induced myeloneuropathy: an emerging public health issue. Ir J Med Sci 2023; 192:383–388.
Zheng D, Ba F, Bi G, et al. The sharp rise of neurological disorders associated with recreational nitrous oxide use in China: a single-center experience and a brief review of Chinese literature. J Neurol 2020; 267:422–429.
Schmitt WP, Rohatgi S, Matiello M. Case 15-2023: a 33-year-old man with paresthesia of the arms and legs. N Engl J Med 2023; 388:1893–1900.
Oussalah A, Julien M, Levy J, et al. Global burden related to nitrous oxide exposure in medical and recreational settings: a systematic review and individual patient data meta-analysis. J Clin Med 2019; 8:551.
Berling E, Fargeot G, Aure K, et al. Nitrous oxide-induced predominantly motor neuropathies: a follow-up study. J Neurol 2022; 269:2720–2726.
Paris A, Lake L, Joseph A, et al. Nitrous oxide-induced subacute combined degeneration of the cord: diagnosis and treatment. Pract Neurol 2023; 23:222–228.
De Vriese AS, Coster RV, Smet J, et al. Linezolid-induced inhibition of mitochondrial protein synthesis. Clin Infect Dis 2006; 42:1111–1117.
Conradie F, Diacon AH, Ngubane N, et al. Treatment of highly drug-resistant pulmonary tuberculosis. N Engl J Med 2020; 382:893–902.
Conradie F, Bagdasaryan TR, Borisov S, et al. Bedaquiline-pretomanid-linezolid regimens for drug-resistant tuberculosis. N Engl J Med 2022; 387:810–823.
WHO. Ciguatera poisoning [date unknown].
Isbister GK, Kiernan MC. Neurotoxic marine poisoning. Lancet Neurol 2005; 4:219–228.
Friedman MA, Fernandez M, Backer LC, et al. An updated review of ciguatera fish poisoning: clinical, epidemiological, environmental, and public health management. Mar Drugs 2017; 15:
Schnorf H, Taurarii M, Cundy T. Ciguatera fish poisoning: a double-blind randomized trial of mannitol therapy. Neurology 2002; 58:873–880.